PHAIT, Inc.

Phait, inc. email format

Verified email-pattern data for Phait, Inc. is currently limited. You can still use the company insights and contact sections below.
PHAIT aims to intercept lung cancer, the deadliest cancer worldwide, by treating pre-cancer dysplasia with oral Iloprost to reduce lung cancer incidence and death. Iloprost is an immuno-modulator repurposed drug that is currently FDA approved, reimbursed, and routinely used for the treatment of pulmonary arterial hypertension (PAH) and Raynaud’s disease. Consequently, Iloprost is de-risked with proven patient safety and tolerance. Daily doses of a proprietary formulation of oral Iloprost, exclusively licensed from Bayer to be manufactured by PHAIT, will provide the therapeutic breakthrough. Oral Iloprost has demonstrated effectiveness in a published Phase 2a clinical study where patients taking the drug for six months responded significantly with precancerous dysplasia reduced by half: https://aacrjournals.org/cancerpreventionresearch/article/4/6/793/49855/Oral-Iloprost-Improves-Endobronchial-Dysplasia-in?searchresult=1.
Looking for a particular PHAIT, Inc. employee's phone or email?

Phait, Inc. Questions

Explore related pages

Related company profiles:

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant